Axia Medical, Keraplast Technologies to Offer Keras Skin Care System to U.S. Physicians

Keraplast Technologies and Axia Medical announced today an exclusive partnership to bring the Keras skin care system to U.S. dermatologists, plastic surgeons, spas and clinics under physician direction.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
dermesse and keras skin care
The exciting healing innovation of Replicine Functional Keratin incorporated in the Keras skin care system significantly improves post treatment care.

Carlsbad, CA (PRWEB) April 11, 2013

Keraplast Technologies and Axia Medical announced today an exclusive partnership to bring the Keras skin care system to U.S. dermatologists, plastic surgeons, spas and clinics under physician direction.

Incorporating the latest advancements in wound treatment, the Keras system uses the proven Replicine™ Functional Keratin® wound care technology to provide improved healing after skin treatments such as chemical peels, microdermabrasion or laser treatments, reducing down time and improving the cosmetic outcome, as well as a full range of at home care products to rebuild skin structure through an ongoing regimen.

“Axia consistently offers the latest in skin innovation to the professional skin care market,” said Jim Krulisky, Chief Executive Officer of Axia Medical. "Our Dermesse products provide trusted solutions for existing skin conditions, such as hyperpigmentation and acne. The exciting healing innovation of Replicine Functional Keratin incorporated in the Keras skin care system significantly improves post treatment care, and our customers will have increased confidence that Axia addresses the complete needs of their patients using well proven innovations."

Peer reviewed scientific publications describe University of Miami research identifying that Replicine™ Functional Keratin® helps speed healing and helps skin cells make more collagen 4 and collagen 7. These particular proteins are crucial for rebuilding healthy skin structure following injury, and are also the specific collagens degraded at the base of each wrinkle during the ageing process. Professor Robert Kirsner, MD, Vice Chairman & Stiefel Laboratories Chair Department of Dermatology & Cutaneous Surgery and Chief of Dermatology University of Miami School of Medicine said: "The understanding of the role that keratin proteins play in skin biology and wound care is emerging science and expanding at a rapid rate. The use of keratin is real innovation and can be seen as a new paradigm in wound healing."

More information on the Keras skin care system is available from http://www.kerasusa.com, or by contacting Axia Medical at 866-494-4466.

Keraplast Technologies LLC, a privately held company founded in 1996, is the world's leading developer and manufacturer of keratin products. Headquartered in San Antonio, Texas, Keraplast manufactures Replicine™ Functional Keratin® wound care products with FDA and CE mark clearance for sale around the world, as well as a wide range of skin care, hair care and nutritional solutions using proprietary keratin technology.

Axia Medical is a well established, privately held, global specialty pharmaceutical company that develops, manufactures, and commercializes skin care products to medical professionals. The medical fields served specialize in dermatologic, aesthetic, and cosmetic procedures. Products include prescription drugs, OTC, and cosmeceutical products under the well known Dermesse brand or under a physician specific Private Label program. The Dermesse products are only available through a physician’s office. Axia is committed to providing superior support to the physicians served and their staff by offering unparalleled customer service. More information is available at http://www.dermesse.com


Contact